Gilead Sciences names Daniel O’Day chairman and CEO
Gilead Sciences’ board of directors has named Daniel O’Day chairman of the board and CEO, effective March 1, 2019.
O’Day is currently the CEO of Roche Pharmaceuticals and has held the position since 2011. Prior to this, he led Roche Diagnostics. His career spans three decades of diverse leadership roles across North America, Asia Pacific and Europe.
Gregg Alton will serve as interim CEO from Jan. 1, 2019 until March 1, 2019. Alton has held a number of executive positions at Gilead over the past 20 years, with experience in legal, medical affairs, policy and commercial. He previously served as general counsel, and in August of this year was appointed chief patient officer.
“Following a comprehensive search, the board became convinced that Dan is the right leader to bring Gilead into the future,” Gilead Sciences' board of directors chairman John Martin said. “He is uniquely qualified to take on this role given his track record of success in highly scientific and competitive therapeutic areas, deep understanding of the evolving healthcare environment around the world, and unwavering commitment to driving innovation across all aspects of a business, which will serve Gilead and our stakeholders well. Additionally, Dan brings expertise and values that are aligned with our organization, and I, along with Gilead’s entire board, am confident in his ability to work alongside our talented leadership team and deliver on our ambitious goals.”
Martin will step down from the company’s board of directors, effective March 1, 2019. John Milligan will step down from his role as president and CEO, and as a member of the board at the end of 2018.
O’Day is currently the CEO of Roche Pharmaceuticals and has held the position since 2011. Prior to this, he led Roche Diagnostics. His career spans three decades of diverse leadership roles across North America, Asia Pacific and Europe.
Gregg Alton will serve as interim CEO from Jan. 1, 2019 until March 1, 2019. Alton has held a number of executive positions at Gilead over the past 20 years, with experience in legal, medical affairs, policy and commercial. He previously served as general counsel, and in August of this year was appointed chief patient officer.
“Following a comprehensive search, the board became convinced that Dan is the right leader to bring Gilead into the future,” Gilead Sciences' board of directors chairman John Martin said. “He is uniquely qualified to take on this role given his track record of success in highly scientific and competitive therapeutic areas, deep understanding of the evolving healthcare environment around the world, and unwavering commitment to driving innovation across all aspects of a business, which will serve Gilead and our stakeholders well. Additionally, Dan brings expertise and values that are aligned with our organization, and I, along with Gilead’s entire board, am confident in his ability to work alongside our talented leadership team and deliver on our ambitious goals.”
Martin will step down from the company’s board of directors, effective March 1, 2019. John Milligan will step down from his role as president and CEO, and as a member of the board at the end of 2018.